News

Gilead Supports Trump HIV Strategy

One of the major aspects of Trump’s platform, when he ran, was to end the HIV epidemic by 2030.

He wanted to make a major step towards this during his presidency.

Gilead, a drug maker that produces HIV prevention medications, has reached an agreement with the White House to help with the Trump strategy.

The Agreement

Gilead Sciences has agreed to donate enough drugs to reduce the risk of HIV transmission for up to 200,000 individuals every year.

The agreement took place between Gilead and the Trump administration and will last through December 31, 2025.

In most instances, Gilead sells through PrEP medication, Truvada, for between $1600 and $2000 a month in the United States.

This will help to reduce the HIV infection risk throughout the United States dramatically.

Trump tweeted about the donation from Gilead, which will last for up to 11 years.

It is a historic donation that will help a large number of individuals.

Gilead is currently dominating the HIV medication market.

The Trump administration will cover the costs associated with distributing the pills.

Approximately 36.9 million people around the world are living with HIV or AIDS.

Approximately 21.7 million of these people are using various anti-retroviral medications in order to suppress the infection.

A Major Step

The Health and Human Services Secretary for the United States, Alex Azar, has identified that this donation is a major step towards achieving the goal for the administration.

It is possible to end the HIV epidemic by the end of 2030.

He goes on to explain that many Americans who are at risk can protect themselves with PrEP.

However, they are still not receiving the necessary medication. This agreement can close the gap significantly.

The infections can be greatly reduced with this move, particularly across the United States.

Plenty of pharmaceutical companies have made efforts to combat the HIV epidemic around the world.

However, it isn’t necessarily helping domestically.

The Kaiser Family Foundation has said that the donation from Gilead will help in this regard.

There is still a major problem that will need to be addressed in regards to the HIV/AIDS fight.

The underlying price issues are still a problem.

The donation is going to give more people access to the treatment.

However, Truvada costs more than $20,000 per patient every single year.

Pres. Trump and the entire health department are working on getting better drug prices.

They are gaining a significant amount of Republican support in order to push towards more affordable pricing, which can give more individuals access to treatment medication.

It seems as though Republicans are willing to tolerate some proposals that are not favored by the industry as a whole.

This includes importing medicine from overseas as well as exploring incremental legislation that has been previously blocked by Congress for years.

Democrats, too, are accepting some of the shifts within the environment.

They are promoting government negotiations with Medicare drug prices.

They are also in favor of government-run drug manufacturing, which can eliminate the pharmaceutical companies and their often subjective pricing strategies entirely.

There are also some changes being made to the Affordable Care Act.

This can help those with HIV/AIDS get the care that they need, including protecting patients with pre-existing conditions.

What’s Next?

The country still has a lot of work in terms of helping those with HIV/AIDS.

The epidemic needs to be controlled.

Although there have been landmark biomedical and scientific research advances, much of it is expensive.

It can also make it difficult to get to everyone throughout the United States.

In February 2019, Trump announced the goal to end the HIV epidemic within 10 years.

One of the components is to reduce new HIV infections by 75% within the first five years and by 90% by 2030.

Government expenditures have also increased.

Approximately $20 billion in direct health expenditures are being spent by the government for HIV prevention and care.

Several phases are in place in order to end the epidemic.

Phase 1 is to focus on the geographic hotspots.

Approximately 50% of new diagnoses happen within 48 counties around the country.

Phase 2 will focus on dissemination across the nation and reducing infections.

Phase 3 will focus on intensive care management to continue to reduce new infections to a number of less than 3000 per year.

There will be challenges, though there are plenty of key strategies in place.

Further, various departments within Health and Human Services are involved, including the Centers for Disease Control and Prevention and the National Institutes of Health.

For now, however, the relationship with Gilead is a huge one, helping to move one step closer to the goals that have been created.